Pharmacological modulation of farnesyltransferase subtype I attenuates mecamylamine-precipitated nicotine withdrawal syndrome in mice

Behavioural Pharmacology

Volumn 24, Issue 8, 2013, Pages 668-677

  Singh, Thakur G ^a   Rehni, Ashish K ^a   Arora, Sandeep K ^a  

^a CHITKARA UNIVERSITY   (India)

Author keywords

Anxiety; Farnesyltransferase; FTI 276; Hyperalgesia; Jumping frequency; Mouse; Nicotine dependence; Withdrawal syndrome

Indexed keywords

MECAMYLAMINE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE TRIFLUOROACETIC ACID; NICOTINE; PROTEIN FARNESYLTRANSFERASE; TRIFLUOROACETIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; GROOMING; HYPERALGESIA; JUMPING; LICKING; MALE; MASTICATION; MAZE TEST; MOUSE; NICOTINE WITHDRAWAL SYNDROME; NONHUMAN; SCANNING ELECTRON MICROSCOPY; SCRATCHING; SMOKING CESSATION; TAIL FLICK TEST; WET DOG SHAKES; WITHDRAWAL SYNDROME;

ANIMALS; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; MALE; MECAMYLAMINE; METHIONINE; MICE; NICOTINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84888179642     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000009     Document Type: Article

References (84)

1. Avidor-Reiss T, Nevo I, Levy R, Pfeuffer T, Vogel Z (1996). Chronic opioid treatment induces adenylyl cyclase v superactivation involvement of Gβγ. J Biol Chem 271:21309-21315. (Pubitemid 26292991)
2. Bae UJ, Lee da Y, Song MY, Lee SM, Park JW, Ryu JH, Park BH (2011). A prenylated flavan from Broussonetia kazinoki prevents cytokine-induced β-cell death through suppression of nuclear factor-kB activity. Biol Pharm Bull 34:1026-1031.
3. Balosso S, Maroso M, Sanchez-Alavez M, Ravizza T, Frasca A, Bartfai T, et al. (2008). A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1beta. Brain 131:3256-3265.
4. Barr J, Sharma CS, Sarkar S, Wise K, Dong L, Periyakaruppan A, et al. (2006). Nicotine induces oxidative stress and activates nuclear transcription factor kappa B in rat mesencephalic cells. Mol Cell Biochem 297:93-99. (Pubitemid 46443533)
5. Berrettini WH, Lerman CE (2005). Pharmacotherapy and pharmacogenetic of nicotine dependence. Am J Psychiatry 162:1441-1451.
6. Biala G, Weglinska B (2005). Blockade of the expression of mecamylamineprecipitated nicotine withdrawal by calcium channel antagonists. Pharmacol Res 51:483-488. (Pubitemid 40321018)
7. Bibevski S, Zhou Y, McIntosh JM, Zigmond RE, Dunlap ME (2000). Functional nicotinic acetylcholine receptors that mediate ganglionic transmission in cardiac parasympathetic neurons. J Neurosci 20:5076-5082. (Pubitemid 30421711)
8. Camí J, Farré M (2003). Drug addiction. N Engl J Med 349:975-986.
9. Capasso A, Sorretino L (1997). Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea pig isolated ileum. Eur J Pharmacol 330:199-204. (Pubitemid 27296723)
10. Capasso A (2001). Involvement of nuclear factor-kB in the expression of opiate withdrawal. Prog Neuropsychopharmacol Biol Psychiatry 25: 1259-1268. (Pubitemid 32835283)
11. Casey PJ, Seabra MC (1996). Protein prenyltransferases. J Biol Chem 271: 5289-5292. (Pubitemid 26083855)
12. Chen WJ, Andres DA, Goldstein JL, Brown MS (1991). Cloning and expression of a cDNA encoding the alpha subunit of rat p21ras protein farnesyltransferase. Proc Natl Acad Sci USA 88:11368-11372. (Pubitemid 21916042)
13. Dajas-Bailador F, Wonnacott S (2004). Nicotinic acetylcholine receptors and the regulation of neuronal signaling. Trends Pharmacol Sci 25:317-324. (Pubitemid 38692424)
14. Damaj MI, Kao W, Martin BR (2003). Characterization of spontaneous and precipitated nicotine withdrawal in the mouse. J Pharmacol Exp Ther 307: 526-534. (Pubitemid 37310665)
15. D'Amour FE, Smith DL (1941). A method for determining loss of pain sensation. J Pharmacol Exp Ther 72:74-79.
16. Deraeve C, Guo Z, Bon RS, Blankenfeldt W, DiLucrezia R, Wolf A, et al. (2012). Psoromic acid is a selective and covalent Rab-prenylation inhibitor targeting auto inhibited RabGGTase. J Am Chem Soc 134:7384-7391.
17. Di Matteo V, Pierucci M, Benigno A, Esposito E, Crescimanno G, Di Giovanni G (2010). Critical role of nitric oxide on nicotine-induced hyperactivation of dopaminergic nigrostriatal system: electrophysiological and neurochemical evidence in rats. CNS Neurosci Ther 16:127-136.
18. Fucile S (2004). Ca2C permeability of nicotinic acetylcholine receptors. Cell Calcium 35:1-8. (Pubitemid 38054783)
19. Gay B, Suarez S, Caravatti G, Furet P, Meyer T, Schoepfer J (1999). Selective GRB2 SH2 inhibitors as anti-Ras therapy. Int J Cancer 83:235-241. (Pubitemid 29449103)
20. Goldstein JL, Brown MS, Stradley SJ, Reiss Y, Geirasch LM (1991). Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase. J Biol Chem 266:15575-15578. (Pubitemid 21907690)
21. Graham TE, Pfeiffer JR, Lee RJ, Kusewitt DF, Martinez AM, Foutz T, et al. (1998). MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling. J Immunol 161:6733-6744. (Pubitemid 28562216)
22. Guo X, Liu ES, Ko JK, Wong BC, Ye Y, Lam S, Cho C (2011). Protective role of cyclooxygenase inhibitors in the adverse action of passive cigarette smoking on the initiation of experimental colitis in rats. Eur J Pharmacol 411:193-203.
23. Hauger RL, Risbrough V, Brauns O, Dautzenberg FM (2006). Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol Disord Drug Targets 5:453-479. (Pubitemid 44203356)
24. Heimdal JH, Aarstad HJ, Klementsen B, Olofsson J (1999). Ex vivo interleukin (IL)-1 beta, IL-6, IL-12 and tumor necrosis factor-alpha responsiveness with monocytes from patients with head and neck carcinoma. Eur Arch Otorhinolaryngol 256:250-256. (Pubitemid 29265422)
25. Hooff GP, Patel N, Wood WG, Müller WE, Eckert GP, Volmer DA (2010). A rapid and sensitive assay for determining human brain levels of farnesyl-(FPP) and geranylgeranylpyrophosphate (GGPP) and transferase activities using UHPLC-MS/MS. Anal Bioanal Chem 398:1801-1808.
26. Ishibashi M, Leonard CS, Kohlmeier KA (2009). Nicotinic activation of laterodorsal tegmental neurons: implications for addiction to nicotine. Neuropsychopharmacology 34:2529-2547.
27. Jackson KJ, Damaj MI (2009). L-type calcium channels and calcium/calmodulindependent kinase II differentially mediate behaviors associated with nicotine withdrawal in mice. J Pharmacol Exp Ther 330:152-161.
28. Jackson KJ, Carroll FI, Negus SS, Damaj MI (2010). Effect of the selective kappaopioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse. Psychopharmacology (Berl) 210:285-294.
29. Jain R, Mukherjee K, Mohan D (2008). Effects of nitric oxide synthase inhibitors in attenuating nicotine withdrawal in rats. Pharmacol Biochem Behav 88: 473-480. (Pubitemid 350266791)
30. Joly A, Popjak G, Edwards PA (1991). In vitro identification of a soluble protein:geranylgeranyl transferase from rat tissues. J Biol Chem 266: 13495-13496.
31. Kiguchi N, Maeda T, Tsuruga M, Yamamoto A, Yamamoto C, Ozaki M, Kishioka S (2008). Involvement of spinal Met-enkephalin in nicotine-induced antinociception in mice. Brain Res 16:70-77. (Pubitemid 351842550)
32. Kinsella BT, Maltese WA (1992). Rab GTP-binding proteins with three different carboxyl-terminal cysteine motifs are modified in vivo by 20-carbon isoprenoids. J Biol Chem 267:3940-3945.
33. Konstantinopoulos PA, Karamouzis MV, Papavassilliou AG (2007). Post translational modifications and regulations of the RAS superfamily of GTPaseas anticancer targets. Nat Rev Drug Discov 6:541-555. (Pubitemid 47019443)
34. Lan H, Teeter MM, Gurevich VV, Neve KA (2009). An intracellular loop 2 amino acid residue determines differential binding of arrestin to the dopamine D2 and D3 receptors. Mol Pharmacol 75:19-26.
35. Lantry LE, Zhang Z, Yao R, Crist KA, Wang Y, Ohkanda J, et al. (2000). Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(nitrosomethylamine)-1-(3-Pyridyl)-1-butanone. Carcinogenesis 21:113-116. (Pubitemid 30064152)
36. Lazzerini PE, Lorenzini S, Selvi E, Capecchi PL, Chindamo D, Bisogno S, et al. (2007). Simvastatin inhibits cytokine production and nuclear factor-kB activation in interleukin 1beta-stimulated synoviocytes from rheumatoid arthritis patients. Clin Exp Rheumatol 25:696-700. (Pubitemid 350284842)
37. Le Foll B, Goldberg SR (2009). Effects of nicotine in experimental animals and humans: an update on addictive properties. Handb Exp Pharmacol 192: 335-367.
38. Le Novère N, Grutter T, Changeux JP (2002). Models of the extracellular domain of the nicotinic receptors and of agonist- and Ca2 +-binding sites. Proc Natl Acad Sci USA 99:3210-3215. (Pubitemid 34240611)
39. Lerner EC, Qian Y, Blaskovich MA, Fossum RD, Vogt A, Sun J, et al. (1995). Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem 270:26802-26806. (Pubitemid 3007240)
40. Li L, Boddul SV, Patil SS, Zheng JF, An G, Höger H, Lubec G (2011). Proteins linked to extinction in contextual fear conditioning in the C57BL/6J mouse. Proteomics 11:3706-3724.
41. Li X, Han J, Li L, Wang KJ, Hu SJ (2013). Effect of farnesyltransferase inhibition on cardiac remodeling in spontaneously hypertensive rats. Int J Cardiol doi: 10.1016/j.ijcard.2013.04.038. [Epub ahead of print].
42. Manuele MG, Barreiro Arcos ML, Davicino R, Ferraro G, Cremaschi G, Anesini C (2010). Limonene exerts antiproliferative effects and increases nitric oxide levels on a lymphoma cell line by dual mechanism of the ERK pathway: relationship with oxidative stress. Cancer Invest 28:135-145.
43. Marks MJ, Stitzel JA, Collins AC (1986). Dose-response analysis of nicotine tolerance and receptor changes in two inbred mouse strains. J Pharmacol Exp Ther 239:358-364. (Pubitemid 17183157)
44. Massonnet B, Normand S, Moschitz R, Delwail A, Favot L, Garcia M, et al. (2009). Pharmacological inhibitors of the mevalonate pathway activate pro-IL-1 processing and IL-1 release by human monocytes. Eur Cytokine Netw 20:112-120.
45. McCarty MF (2003). Reduction of serum C-reactive protein by statin therapy may reflect decreased isoprenylation of Rac-1, a mediator of the IL-6 signal transduction pathway. Med Hypotheses 60:634-639. (Pubitemid 36399290)
46. Merjonen P, Keltikangas-Järvinen L, Jokela M, Seppälä I, Lyytikäinen LP, Pulkki-Råback L, et al. (2011). Hostility in adolescents and adults: a genome-wide association study of the Young Finns. Transl Psychiatry 1:e11.
47. Millar JS, Ky B, Wolfe ML, Pruscino L, Baer A, Rader DJ (2010). Short-term treatment with high-dose atorvastatin reduces LDL cholesterol but shows no anti-inflammatory effects in normolipidemic subjects with normal CRP levels. Clin Transl Sci 3:140-146.
48. Miller LJ, Dong M, Harikumar KG, Gao F (2007). Structural basis of natural ligand binding and activation of the class II G-protein-coupled secretin receptor. Biochem Soc Trans 35:709-712. (Pubitemid 47310350)
49. Mulligan T, Blasér H, Raz E, Farber SA (2012). Prenylation deficient G protein gamma subunits disrupt GPCR signalling in the zebrafish. Cell Signal 22:221-233.
50. Naha N, Lee HY, Hwang JS, Bahk JY, Park MS, Lee SY, et al. (2009). Nicotine tolerance to PC12 cell line: acute and chronic exposures modulate dopamine D(2) receptor and tyrosine hydroxylase expression. Neurol Res 31:289-299.
51. Nakao S, Ogata Y, Sugiya H (2009). Nicotine stimulates the expression of cyclooxygenase-2 mRNA via NFkappaB activation in human gingival fibroblasts. Arch Oral Biol 54:251-257.
52. Navarro JF, Buron E, Martin-Lopez M (2006). Anxiolytic-like activity of SB-205384 in the elevated plus maze test in mice. Psicothema 18:100-104. (Pubitemid 44681996)
53. Nunes SO, Vargas HO, Brum J, Prado E, Vargas MM, de Castro MR, et al. (2012). A comparison of inflammatory markers in depressed and nondepressed smokers. Nicotine Tob Res 14:540-546.
54. Pace E, Ferraro M, Uasuf CG, Giarratano A, La Grutta S, Liotta G, et al. (2011). Cilomilast counteracts the effects of cigarette smoke in airway epithelial cells. Cell Immunol 2268:47-53.
55. Pauly JR, Grun EU, Collins AC (1992). Tolerance to nicotine following chronic treatment by injections: a potential role for corticosterone. Psychopharmacology (Berl) 108:33-39.
56. Pohanka M (2012). Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicology. Int J Mol Sci 13:2219-2238.
57. Pollack IF, Bredel M, Erff M, Hamilton AD, Sebti SM (1999). Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II - preclinical studies in a nude mouse model. Neurosurgery 45:1208-1214.
58. Portugal GS, Gould TJ (2009). Nicotine withdrawal disrupts new contextual learning. Pharmacol Biochem Behav 92:117-123.
59. Poth K, Nutter TJ, Cuevas J, Parker MJ, Adams DJ, Luetje CW (1997). Heterogeneity of nicotinic receptor class and subunit mRNA expression among individual parasympathetic neurons from rat intracardiac ganglia. J Neurosci 17:586-596. (Pubitemid 27024571)
60. Rehni AK, Bhateja P, Singh TG, Singh N (2008). Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome. Behav Pharmacol 19: 265-269. (Pubitemid 351670407)
61. Rehni AK, Singh N, Rachamalla M, Tikoo K (2012a). Modulation of histone deacetylase attenuates naloxone-precipitated opioid withdrawal syndrome. Naunyn Schmiedebergs Arch Pharmacol 385:605-619.
62. Rehni AK, Singh TG, Arora S (2012b). SU-6656, a selective Src kinase inhibitor, attenuates mecamylamine-precipitated nicotine withdrawal syndrome in mice. Nicotine Tob Res 14:407-414.
63. Rehni AK, Singh TG (2013). Pharmacological modulation of geranylgeranyltransferase and farnesyltransferase attenuates opioid withdrawal in vivo and in vitro. Neuropharmacology 71:19-26.
64. Reiss YJL, Goldstein MC, Seabra PJC, Brown MS (1990). Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell 62: 81-88.
65. Reuveni H, Geiger T, Geiger B, Levitzki A (2000). Reversal of the Ras-induced transformed phenotype by HR12, a novel ras farnesylation inhibitor, is mediated by the Mek/Erk pathway. J Cell Biol 151:1179-1192.
66. Roberts PJ, Der CJ (2007). Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291-3310. (Pubitemid 46763022)
67. Ross J, Rosen G (2002). The molecular biology of lung cancer. Curr Opin Pulm Med 8:265-269. (Pubitemid 34625958)
68. Rowinsky ER, Windle JJ, van Hoff DD (1999). Ras protein farnesyltransferase: a strategic target for anticancer therapeutics development. J Clin Oncol 17:3631-3652. (Pubitemid 29517936)
69. Shin VY, Jin HC, Ng EK, Yu J, Leung WK, Cho CH, Sung JJ (2008). Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induce cyclooxygenase-2 activity in human gastric cancer cells: Involvement of nicotinic acetylcholine receptor (nAChR) and beta-adrenergic receptor signaling pathways. Toxicol Appl Pharmacol 233:254-261. (Pubitemid 50301023)
70. Sirota AD, Rohsenow DJ, Dolan SL, Martin RA, Kahler CW (2013). Intolerance for discomfort among smokers: comparison of smoking-specific and nonspecific measures to smoking history and patterns. Addict Behav 38: 1782-1787.
71. Steelman LS, Chappell WH, Abrams SL, Kempf CR, Long J, Laidler P, et al. (2011). Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 3:192-222.
72. Stoker AK, Semenova S, Markou A (2008). Affective and somatic aspects of spontaneous and precipitated nicotine withdrawal in C57BL/6J and BALB/cByJ mice. Neuropharmacology 54:1223-1232.
73. Stubbs EB, Von Zee CL (2012). Prenylation of Rho G-proteins: a novel mechanism regulating gene expression and protein stability in human trabecular meshwork cells. Mol Neurobiol 46:28-40.
74. Sun J, Qian Y, Hamilton AD, Sebti SM (1998). Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic KRas prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 16:1467-1473. (Pubitemid 28151853)
75. Teramoto H, Coso OA, Miyata H, Igishi T, Miki T, Gutkind JS (1996). Signaling from the small GTP-binding proteins Rac1 and Cdc42 to the c-Jun N-terminal kinase/stress-activated protein kinase pathway. A role for mixed lineage kinase 3/protein-tyrosine kinase 1, a novel member of the mixed lineage kinase family. J Biol Chem 271:27225-27228. (Pubitemid 26367270)
76. Thompson C, Cloutier A, Bossé Y, Thivierge M, Gouil CL, Larivée P, et al. (2006). CysLT1 receptor engagement induces activator protein-1- and NF-kappaBdependent IL-8 expression. Am J Respir Cell Mol Biol 35:697-704. (Pubitemid 44901859)
77. Vançelik S, Beyhun NE, Acemoǧ lu H (2009). Interactions between exhaled CO, smoking status and nicotine dependency in a sample of Turkish adolescents. Turk J Pediatr 51:56-64.
78. Walton R, Johnstone E, Munafò M, Neville M, Griffiths S (2001). Genetic clues to the molecular basis of tobacco addiction and progress towards personalized therapy. Trends Mol Med 7:70-76. (Pubitemid 33718645)
79. Wilkes S (2006). Bupropion. Drugs Today (Barc) 42:671-681. (Pubitemid 44901641)
80. Yoshikawa H, Kurokawa M, Ozaki N, Nara K, Atou K, Takada E, et al. (2006). Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-kappaB phosphorylation and nuclear factorkappaB transcriptional activity through nicotinic acetylcholine receptor alpha N7. Clin Exp Immunol 146:116-123. (Pubitemid 44393846)
81. Yu G, Chen H, Wu X, Matta SG, Sharp BM (2010). Nicotine self-administration differentially modulates glutamate and GABA transmission in hypothalamic paraventricular nucleus to enhance the hypothalamic-pituitary- adrenal response to stress. J Neurochem 113:919-929.
82. Zaparoli JX, Galduróz JC (2012). Treatment for tobacco smoking: a new alternative? Med Hypotheses 79:867-868.
83. Zhu B, Heeschen C, Sievers RE, Karliner JS, Parmley WW, Glantz SA, Cooke JP (2003). Second hand smoke stimulates tumor angiogenesis and growth. Cancer Cell 4:191-196. (Pubitemid 37163833)
84. Zhuravliova E, Barbakadze T, Narmania N, Ramsden J, Mikeladze D (2007). Inhibition of nitric oxide synthase and farnesyltransferase change the activities of several transcription factors. J Mol Neurosci 31:281-287. (Pubitemid 47338420)